Rallybio (NASDAQ:RLYB) Receives “Buy” Rating from HC Wainwright

HC Wainwright reaffirmed their buy rating on shares of Rallybio (NASDAQ:RLYB) in a research note released on Monday morning,Benzinga reports. They currently have a $5.00 target price on the stock. HC Wainwright also issued estimates for Rallybio’s FY2025 earnings at ($1.20) EPS.

Rallybio Stock Performance

Shares of NASDAQ RLYB opened at $0.73 on Monday. The company has a market capitalization of $30.24 million, a P/E ratio of -0.46 and a beta of -1.45. Rallybio has a 52-week low of $0.62 and a 52-week high of $3.46. The company’s 50 day moving average price is $0.79 and its 200-day moving average price is $0.97.

Rallybio (NASDAQ:RLYB) last issued its quarterly earnings results on Thursday, March 13th. The company reported ($0.25) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.27) by $0.02. The firm had revenue of $0.04 million during the quarter, compared to analyst estimates of $0.15 million. Analysts forecast that Rallybio will post -1.34 earnings per share for the current year.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the stock. Northeast Financial Consultants Inc lifted its position in shares of Rallybio by 336.5% during the 4th quarter. Northeast Financial Consultants Inc now owns 96,422 shares of the company’s stock valued at $93,000 after acquiring an additional 74,334 shares during the period. Geode Capital Management LLC increased its stake in Rallybio by 11.4% during the 3rd quarter. Geode Capital Management LLC now owns 244,986 shares of the company’s stock valued at $287,000 after purchasing an additional 24,980 shares in the last quarter. Renaissance Technologies LLC increased its stake in Rallybio by 9.3% during the 4th quarter. Renaissance Technologies LLC now owns 441,318 shares of the company’s stock valued at $424,000 after purchasing an additional 37,618 shares in the last quarter. Allostery Investments LP bought a new stake in Rallybio during the 4th quarter valued at $771,000. Finally, Almitas Capital LLC increased its stake in Rallybio by 48.3% during the 4th quarter. Almitas Capital LLC now owns 1,298,119 shares of the company’s stock valued at $1,246,000 after purchasing an additional 422,685 shares in the last quarter. Institutional investors and hedge funds own 90.34% of the company’s stock.

About Rallybio

Rallybio Corporation, a clinical-stage biotechnology company, engages in development and commercialization of life-transforming therapies for patients suffering from severe and rare diseases. Its lead product candidate is RLYB212, a monoclonal anti-HPA-1a antibody that has completed Phase I clinical trial for the prevention of fetal and neonatal alloimmune thrombocytopenia (FNAIT); and RLYB211 for the prevention of FNAIT.